Please login to the form below

Not currently logged in

UCB integrates two CROs into its clinical trial teams

Belgium pharma company agrees global research outsourcing deal with Parexel and PRA

UCB has signed partnership deals with two contract research organisations (CROs) that will see them operate as part of its global drug development team.

The agreements with Parexel and PRA will cover all the Brussels-based pharma company's new clinical trial programmes and they are also aimed at making UCB's studies more efficient and cost effective.

UCB's chief medical officer Iris Loew-Friedrich said: "We are pleased to announce these strategic partnerships as UCB aims to expand its global drug development activities, including in Asia.

“These partnerships represent long-term, win-win commitments to an outsourcing model focused on maximising the effectiveness of each participant's resources in clinical operations.”

The new arrangements will essentially see Parexel and PRA become integrated members of UCB's study teams, Loew-Friedrich added.

The company was light on the detail of the new agreements, saying the two CROs would “drive UCB's operational clinical development activities” and provide focused global operational clinical development activities.

Parexel said its service offering to UCB would include consulting expertise in regulatory affairs and commercialisation, while PRA said it has services for clinical studies across all phases and therapeutic areas with particular experience in CNS indications.

17th November 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...